An analysis of recent U.S. Senate hearings on menopause care, FDA expert panels on female-dosed testosterone, and efforts to improve hormone treatment access.
On September 16, 2026, the United States Senate held what the Los Angeles Times described as its first hearing on federally funded menopause research and gaps in care. Within 24 hours of that event, the Department of Health and Human Services convened manufacturers to address estradiol patch access, while the FDA gathered expert panels to review female-dosed testosterone.
The historical standard of care for midlife hormonal changes involved significant gaps in clinical funding and fragmented regulatory oversight. Federal policy traditionally offered minimal intervention when patients faced localized treatment shortages or outdated prescribing guidance. Furthermore, doctors treating menopausal women frequently relied on off-label prescribing for hormones like testosterone. This approach left patients without formal, female-specific FDA indications to guide their care.
The recent governmental actions highlight several specific developments in midlife medical policy. According to the Los Angeles Times report, the coordinated federal effort produced several notable moments.
Jennifer Weiss-Wolf was one of four expert witnesses to testify at the September Senate hearing. Writing for the Los Angeles Times, she characterized the congressional attention as a "true bipartisan endeavor" to address women's health. She described the sudden flurry of federal activity across multiple agencies as a "refreshing change" after decades of policy failures. Weiss-Wolf also noted an "alarming lack of availability" of estradiol patches, a concern that prompted the subsequent federal manufacturer meetings.
The historic lack of federal attention has deeply shaped how women experience midlife healthcare. Weiss-Wolf argued in her testimony that decades of policy failures have left substantial gaps in care. This underinvestment means many foundational questions about midlife female biology remain unanswered.
The Senate hearing sought to address these exact research deficits directly. By bringing expert witnesses before lawmakers, the hearing highlighted the urgent need for funded clinical trials. Without dedicated federal funding, large-scale studies on the safety and efficacy of various treatments often stall. This leaves clinicians relying on older data or fragmented smaller studies to guide their patients.
When research lags, clinical training naturally suffers. Medical students and residents frequently receive limited instruction specifically focused on menopause management. This training gap forces many women to seek out specialized providers or navigate conflicting information alone. The recent congressional attention signals a growing recognition that this educational deficit stems directly from a lack of funded science.
The full day of expert panels on female-dosed testosterone marks an important regulatory step. Currently, testosterone is FDA-approved only for men. Menopausal women have long used the hormone off-label for various physical changes. Off-label prescribing is a common medical practice where doctors prescribe a medication without specific FDA clearance for that exact condition.
The FDA panels reviewed the current state of clinical evidence. The meetings focused heavily on access and policy discussions rather than immediately issuing new treatment guidelines. The Los Angeles Times article notes that these sessions did not result in an immediate FDA decision. They also did not propose a new standard dose or announce new clinical-trial findings.
Women navigating these transitions need to know that an expert panel meeting is not an approval. The panels did not establish testosterone as a general treatment for midlife energy, mood or shifting body composition. Patients discussing perimenopause and menopause changes with their doctors should understand this distinction. Prescribing remains off-label for now, and individual decisions still require careful medical supervision.
The current status of testosterone treatment perfectly illustrates the challenges created by delayed clinical research. Because testosterone is approved only for men, its use in female patients happens entirely off-label. Doctors frequently use approved medications to treat unlisted conditions when they believe the evidence supports it.
The lack of a female-specific FDA approval creates practical hurdles. It means there are no federally standardized dosages, administration routes or pharmaceutical products designed specifically for menopausal women. Clinicians must adapt male-dosed products or rely on compounding pharmacies to achieve appropriate female dosing.
This lack of standardization complicates patient care significantly. It makes it harder to monitor consistency across different prescriptions and increases the risk of dosing errors. The FDA expert panels spent a full day reviewing the available data surrounding these exact challenges. Their focus on access and policy reflects a clear need to bring order to an unstandardized treatment landscape.
Estradiol patches remain a common treatment choice for many women managing hormonal transitions. The Department of Health and Human Services stepped in quickly following the Senate hearing to address supply concerns. They convened physicians and drug manufacturers to discuss the availability of these specific treatments.
While the Los Angeles Times article describes the supply issue as alarming, it does not quantify the exact shortage. The report does not list the specific manufacturer names involved in the meeting. It also provides no timeline for when patients might see improved pharmacy availability.
This federal involvement shows regulatory awareness of the access problem. Still, it does not guarantee immediate relief at local pharmacies. Patients facing localized shortages may still need to consult their clinicians about alternative preparations or different pharmacies. Navigating these practical hurdles remains a key part of managing midlife health resources effectively.
The ongoing policy shifts extend back to a significant regulatory change in late 2025. In November 2025, the FDA officially removed the "black box" warning on estrogen products for menopause. The Los Angeles Times report notes this change followed a decade-long effort by physicians, researchers and scientists to secure more accurate labeling.
Removing this warning reflects an evolving understanding of hormone safety. It does not mean that hormone therapy suits every woman. Individual risk assessment remains a vital step in safe clinical care. Clinicians must still evaluate personal health history, cardiovascular risks and individual symptoms before recommending estrogen products.
Beyond systemic treatments, localized care also faces structural challenges. Local vaginal estrogen is frequently overlooked or denied during patient consultations. The article attributes this to outdated clinical guidance and inadequate clinician training. Additionally, Medicare does not routinely cover these localized treatments. This forces many older women to pay out of pocket for recognized medical care.
While federal agencies debate broad regulatory frameworks, state governments are taking immediate legislative action. The introduction of over 60 bills across 28 states shows a rapid acceleration in local health policy. These state-level initiatives often address the practical, daily barriers women face when seeking care.
By October 3, 2026, the successful enactment of 21 laws in ten states created a patchwork of new patient protections. State laws can influence insurance coverage mandates, clinical reporting requirements and public health education funding. Because federal change can take years, state legislatures frequently serve as the first line of policy reform.
California's approach highlights how states can tackle specific regulatory friction points. AB 82 removed the requirement to log testosterone prescriptions in the state tracking database. This change directly reduces the administrative burden on doctors prescribing off-label treatments for women. By easing this reporting requirement, the state aimed to streamline patient access to care.
Another pending measure, AB 1778, would further alter testosterone's legal classification in California pending federal action. California's 2026 budget also included a $3.4-million measure dedicated to menopause education and making treatments more accessible. However, the Los Angeles Times article notes that Medi-Cal patients were not fully covered by this specific measure.
The discussion between health officials and the American Urological Association highlights a frequently ignored aspect of aging. Postmenopausal women face a significantly increased risk of recurrent urinary tract infections. This vulnerability stems directly from the loss of estrogen in the pelvic region.
Estrogen helps maintain the thickness, elasticity and healthy bacterial balance of the vaginal and urinary tissues. As hormone levels drop, these tissues become thinner and more fragile. The local microbiome changes, allowing harmful bacteria to colonize the urinary tract more easily. This physiological shift turns a common nuisance into a persistent health threat for many women.
The federal focus on urosepsis brings necessary attention to the severe consequences of these recurrent infections. Urosepsis is a serious, systemic response to an infection originating in the urinary tract. It requires immediate medical intervention and can be life-threatening if left untreated. Recognizing recurrent urinary tract infections as a major postmenopausal health risk is vital for comprehensive preventative care. The federal meeting underscores that menopause care requires a comprehensive medical approach, connecting physical symptoms with strength, body composition and metabolism changes.
Following health policy news can feel overwhelming for women trying to make practical medical decisions today. The flurry of Senate hearings, FDA panels and state legislation clearly indicates positive momentum. However, policy changes do not instantly alter the reality of scheduling an appointment or filling a prescription.
Patients must bridge the gap between national headlines and their own localized care. When the news reports an alarming lack of availability of patches, patients should proactively check with their pharmacies. Understanding potential supply chain delays allows women to request refills early or discuss alternative formats with their doctors before running out.
In the same way, news about FDA expert panels should prompt informed questions rather than immediate demands for unapproved treatments. Women interested in how hormones affect skin, hair and aesthetic aging should discuss the limits of current evidence with their providers. The goal is to use policy news as a starting point for better clinical conversations.
The combined impact of these federal and state actions creates a new environment for medical dialogue. When government agencies publicly address midlife women's health, it validates the physical reality of the hormonal transition. This validation encourages more women to bring their concerns to qualified healthcare providers.
Open conversations become easier when patients know that regulatory bodies acknowledge their medical needs. Hearing that the FDA spent a full day discussing female-dosed testosterone can prompt a patient to ask informed questions. It removes the stigma that sometimes surrounds seeking care for complex midlife symptoms.
At the same time, this public dialogue places a heavier responsibility on medical professionals. Clinicians must stay informed about evolving regulations, state laws and shifting safety labels. They must carefully translate high-level policy news into actionable advice for the person sitting in their examination room. Women must continue to advocate for themselves during clinical visits, discussing the nutrition and weight management aspects of midlife with clear, personalized guidance.
While federal panels do not immediately rewrite individual prescriptions, these high-level regulatory evaluations indicate a definitive shift toward formally standardizing menopause treatments in clinical practice.
Distinguishing between early government policy discussions and proven clinical treatments requires careful analysis, which is exactly how Refemina approaches the available evidence. We address the confusion surrounding changes in strength, muscle, body composition, metabolism or weight, translating credible research into clear adult guidance without symptom panic. Explore Resources
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources